Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1825 1
1844 1
1848 1
1849 1
1855 3
1866 2
1869 2
1873 5
1876 1
1892 1
1893 2
1895 2
1897 1
1898 3
1899 1
1900 2
1903 2
1904 1
1905 4
1907 1
1908 1
1909 2
1910 1
1911 2
1912 2
1913 3
1914 1
1915 1
1916 1
1917 2
1918 5
1919 4
1920 3
1921 2
1922 3
1924 3
1925 5
1926 4
1927 2
1928 2
1930 4
1931 2
1932 2
1934 1
1936 1
1938 1
1939 1
1941 1
1942 1
1944 1
1945 8
1946 34
1947 13
1948 113
1949 76
1950 106
1951 99
1952 114
1953 103
1954 136
1955 118
1956 112
1957 119
1958 124
1959 82
1960 4
1961 7
1962 6
1963 112
1964 184
1965 153
1966 103
1967 156
1968 132
1969 152
1970 130
1971 128
1972 167
1973 150
1974 149
1975 360
1976 429
1977 385
1978 449
1979 585
1980 629
1981 740
1982 853
1983 1050
1984 1148
1985 1145
1986 1182
1987 1280
1988 1314
1989 1623
1990 1625
1991 1690
1992 1798
1993 2063
1994 2154
1995 2229
1996 2394
1997 2525
1998 2685
1999 2796
2000 3239
2001 3273
2002 3605
2003 3944
2004 4354
2005 4838
2006 5334
2007 5913
2008 6598
2009 7039
2010 7920
2011 9278
2012 10256
2013 11971
2014 13072
2015 14054
2016 15043
2017 16336
2018 17387
2019 18836
2020 22026
2021 25560
2022 25932
2023 25004
2024 9904

Text availability

Article attribute

Article type

Publication date

Search Results

289,535 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for met for
Search for Meet Gor instead (1 results)
Overview of Molecular Detection Technologies for MET in Lung Cancer.
Heydt C, Ihle MA, Merkelbach-Bruse S. Heydt C, et al. Cancers (Basel). 2023 May 26;15(11):2932. doi: 10.3390/cancers15112932. Cancers (Basel). 2023. PMID: 37296895 Free PMC article. Review.
MET tyrosine kinase receptor pathway activation has become an important actionable target in solid tumors. Aberrations in the MET proto-oncogene, including MET overexpression, the activation of MET mutations, MET mutations that lead to MET …
MET tyrosine kinase receptor pathway activation has become an important actionable target in solid tumors. Aberrations in the MET …
An Observatory for the MET Oncogene: A Guide for Targeted Therapies.
Altintas DM, Comoglio PM. Altintas DM, et al. Cancers (Basel). 2023 Sep 21;15(18):4672. doi: 10.3390/cancers15184672. Cancers (Basel). 2023. PMID: 37760640 Free PMC article. Review.
The pleiotropic physiological functions of MET explain its diverse role in cancer progression in a broad range of tumors; genetic/epigenetic alterations of MET drive tumor cell dissemination, metastasis, and acquired resistance to conventional and targeted therapies …
The pleiotropic physiological functions of MET explain its diverse role in cancer progression in a broad range of tumors; genetic/epi …
Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC.
Jørgensen JT, Mollerup J. Jørgensen JT, et al. Cancers (Basel). 2022 Apr 26;14(9):2150. doi: 10.3390/cancers14092150. Cancers (Basel). 2022. PMID: 35565287 Free PMC article. Review.
An alternative predictive biomarker for MET therapy is MET amplification, which has been identified as a resistance mechanism in patients with EGFR-mutated NSCLC. Results obtained from different clinical trials seem to indicate that the MET/CEP7 ratio detecte …
An alternative predictive biomarker for MET therapy is MET amplification, which has been identified as a resistance mechanism …
MET Inhibitors for the Treatment of Gastric Cancer: What's Their Potential?
El Darsa H, El Sayed R, Abdel-Rahman O. El Darsa H, et al. J Exp Pharmacol. 2020 Oct 6;12:349-361. doi: 10.2147/JEP.S242958. eCollection 2020. J Exp Pharmacol. 2020. PMID: 33116950 Free PMC article. Review.
Tyrosine kinase inhibitors targeting the HGF/MET pathway were studied in MET-positive gastric cancer, but no substantial benefit was proven. ...Etiologies of resistance may entail inappropriate patient selection with a lack of MET detection standardization, t …
Tyrosine kinase inhibitors targeting the HGF/MET pathway were studied in MET-positive gastric cancer, but no substantial benef …
MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Guo R, Luo J, Chang J, Rekhtman N, Arcila M, Drilon A. Guo R, et al. Nat Rev Clin Oncol. 2020 Sep;17(9):569-587. doi: 10.1038/s41571-020-0377-z. Epub 2020 Jun 8. Nat Rev Clin Oncol. 2020. PMID: 32514147 Free PMC article. Review.
Thus, MET expression in the absence of a genomic marker of MET dependence is a poor predictor of benefit from MET-targeted therapy. ...The activity of MET tyrosine kinase inhibitors varies by MET alteration category. ...
Thus, MET expression in the absence of a genomic marker of MET dependence is a poor predictor of benefit from MET-targe …
Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer.
Garon EB, Brodrick P. Garon EB, et al. Drugs. 2021 Apr;81(5):547-554. doi: 10.1007/s40265-021-01477-2. Epub 2021 Feb 27. Drugs. 2021. PMID: 33638808 Review.
Unlike MET overexpression, MET amplification has demonstrated a stronger potential as a biomarker for therapeutic treatment, with clinical data indicating a compelling connection between a high MET gene copy number and a high response rate to targeted therapi …
Unlike MET overexpression, MET amplification has demonstrated a stronger potential as a biomarker for therapeutic treatment, w …
MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.
Kawakami H, Okamoto I. Kawakami H, et al. Gastric Cancer. 2016 Jul;19(3):687-95. doi: 10.1007/s10120-015-0585-x. Epub 2015 Dec 21. Gastric Cancer. 2016. PMID: 26690587 Review.
The MET protooncogene encodes the receptor tyrosine kinase c-MET (MET). ...On the other hand, gastric cancer cells with MET amplification are dependent on MET signaling for their survival and are thus vulnerable to MET TKI treatment. ...
The MET protooncogene encodes the receptor tyrosine kinase c-MET (MET). ...On the other hand, gastric cancer cells with …
Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Fujino T, Suda K, Mitsudomi T. Fujino T, et al. Expert Opin Emerg Drugs. 2020 Sep;25(3):229-249. doi: 10.1080/14728214.2020.1791821. Epub 2020 Jul 16. Expert Opin Emerg Drugs. 2020. PMID: 32615820 Review.
Introduction MET aberrations, including MET exon 14 skipping mutation and amplification, are present in ~5% of non-small cell lung cancer (NSCLC) cases, and these levels are comparable to the frequency of ALK fusion. ...Therefore, the development of therapies for ac …
Introduction MET aberrations, including MET exon 14 skipping mutation and amplification, are present in ~5% of non-small cell …
MET in Non-Small-Cell Lung Cancer (NSCLC): Cross 'a Long and Winding Road' Looking for a Target.
Spitaleri G, Trillo Aliaga P, Attili I, Del Signore E, Corvaja C, Corti C, Uliano J, Passaro A, de Marinis F. Spitaleri G, et al. Cancers (Basel). 2023 Sep 28;15(19):4779. doi: 10.3390/cancers15194779. Cancers (Basel). 2023. PMID: 37835473 Free PMC article. Review.
Non-Small-Cell Lung Cancer (NSCLC) can harbour different MET alterations, such as MET overexpression (MET OE), MET gene amplification (MET AMP), or MET gene mutations. Retrospective studies of surgical series of patients with MET-d …
Non-Small-Cell Lung Cancer (NSCLC) can harbour different MET alterations, such as MET overexpression (MET OE), MET …
MET targeted therapy for lung cancer: clinical development and future directions.
Feng Y, Ma PC. Feng Y, et al. Lung Cancer (Auckl). 2012 Aug 9;3:53-67. doi: 10.2147/LCTT.S23423. eCollection 2012. Lung Cancer (Auckl). 2012. PMID: 28210125 Free PMC article. Review.
The MET pathway can be activated through ligand (hepatocyte growth factor, HGF) or MET receptor overexpression, genomic amplification, MET mutations, and alternative splicing. ...Phase III studies of MET targeting agents have recently been initiated. T …
The MET pathway can be activated through ligand (hepatocyte growth factor, HGF) or MET receptor overexpression, genomic amplif …
289,535 results
You have reached the last available page of results. Please see the User Guide for more information.